* If you want to update the article please login/register
This is a non-interventional, multi center authorization safety study that includes all patients diagnosed as Unresectable Differentiated Thyroid Carcinoma and treated with Sorafenib within a set period. As the treatment with NEXAVAR is started, the patient's observation period begins. Information on the patient's health, survival, and squamous cell cancer formation of keratoacanthoma and/or squamous cell carcinoma formation will be collected by those patients, to whom a total of 24 month follow-up is likely, will be available.
Source link: https://clinicaltrials.gov/ct2/show/NCT02185560
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions